| Journal of Nanobiotechnology | |
| Exosomes derived from human adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline metabolism | |
| Research | |
| Jie Chen1  Qinyan Yang2  Xiaolun Huang2  Jin Shang2  Chunyou Lai2  Yuxin Liang2  Su Yan2  Tianhang Feng2  Deyuan Zhong2  Zonglin Dai2  Zilong Zhang2  Haibo Zou2  Ying Shi2  Yutong Yao2  Yuhao Su2  Lelin Sun3  | |
| [1] Department of Core laboratory, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, 610072, Chengdu, Sichuan, China;Liver Transplantation Center and HBP Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital Affiliate to University of Electronic Science and Technology of China, 610042, Chengdu, Sichuan, China;School of Medicine, University of Electronic Science and Technology of China, 610054, Chengdu, Sichuan, China;School of Medicine, University of Electronic Science and Technology of China, 610054, Chengdu, Sichuan, China; | |
| 关键词: Liver fibrosis; Human adipose mesenchymal stem cells; Exosomes; Metabolomics; Choline; | |
| DOI : 10.1186/s12951-023-01788-4 | |
| received in 2022-09-04, accepted in 2023-01-17, 发布年份 2023 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
Liver fibrosis is a chronic liver disease with the presence of progressive wound healing response caused by liver injury. Currently, there are no approved therapies for liver fibrosis. Exosomes derived from human adipose mesenchymal stem cells (hADMSCs-Exo) have displayed a prominent therapeutic effect on liver diseases. However, few studies have evaluated therapeutic effect of hADMSCs-Exo in liver fibrosis and cirrhosis, and its precise mechanisms of action remain unclear. Herein, we investigated anti-fibrotic efficacy of hADMSCs-Exo in vitro and in vivo, and identified important metabolic changes and the detailed mechanism through transcriptomic and metabolomic profiling. We found hADMSCs-Exo could inhibit the proliferation of activated hepatic stellate cells through aggravating apoptosis and arresting G1 phase, effectively inhibiting the expression of profibrogenic proteins and epithelial-to-mesenchymal transition (EMT) in vitro. Moreover, it could significantly block collagen deposition and EMT process, improve liver function and reduce liver inflammation in liver cirrhosis mice model. The omics analysis revealed that the key mechanism of hADMSCs-Exo anti-hepatic fibrosis was the inhibition of PI3K/AKT/mTOR signaling pathway and affecting the changes of metabolites in lipid metabolism, and mainly regulating choline metabolism. CHPT1 activated by hADMSCs-Exo facilitated formation and maintenance of vesicular membranes. Thus, our study indicates that hADMSCs-Exo can attenuate hepatic stellate cell activation and suppress the progression of liver fibrosis, which holds the significant potential of hADMSCs-Exo for use as extracellular nanovesicles-based therapeutics in the treatment of liver fibrosis and possibly other intractable chronic liver diseases.Graphical Abstract
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202305119473495ZK.pdf | 11051KB | ||
| 41116_2022_35_Article_IEq452.gif | 1KB | Image | |
| Fig. 5 | 36KB | Image | |
| 41116_2022_35_Article_IEq503.gif | 1KB | Image | |
| 41116_2022_35_Article_IEq525.gif | 1KB | Image | |
| Fig. 2 | 288KB | Image | |
| 41116_2022_35_Article_IEq575.gif | 1KB | Image | |
| 41116_2022_35_Article_IEq659.gif | 1KB | Image | |
| Fig. 6 | 169KB | Image | |
| Fig. 10 | 507KB | Image | |
| MediaObjects/12888_2022_4438_MOESM1_ESM.jpg | 573KB | Other |
【 图 表 】
Fig. 10
Fig. 6
41116_2022_35_Article_IEq659.gif
41116_2022_35_Article_IEq575.gif
Fig. 2
41116_2022_35_Article_IEq525.gif
41116_2022_35_Article_IEq503.gif
Fig. 5
41116_2022_35_Article_IEq452.gif
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
PDF